Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR

Nicolas M. Van Mieghem, Martin Unverdorben, the ENVISAGE-TAVI AF Investigators, Christian Hengstenberg, Helge Möllmann, Roxana Mehran, Diego López-Otero, Luis Nombela-Franco, Raul Moreno, Peter Nordbeck, Holger Thiele, Irene Lang, José L. Zamorano, Fayaz Shawl, Masanori Yamamoto, Yusuke Watanabe, Kentaro Hayashida, Rainer Hambrecht, Felix Meincke, Pascal VranckxJames Jin, Eric Boersma, Josep Rodés-Cabau, Patrick Ohlmann, Piera Capranzano, Hyo Soo Kim, Thomas Pilgrim, Richard Anderson, Usman Baber, Anil Duggal, Petra Laeis, Hans Lanz, Cathy Chen, Marco Valgimigli, Roland Veltkamp, Shigeru Saito, George D. Dangas*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

31 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR'. Together they form a unique fingerprint.

Medicine & Life Sciences